ARDELYX, INC. Amortization of Advance Royalty
ARDELYX, INC. (ARDX) reported Amortization of Advance Royalty of $3.92 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfAdvanceRoyalty · last filed 2024-02-22
- ARDELYX, INC. amortization of advance royalty for the quarter ending 2023-12-31 was $1.06M, a 28.00% increase year-over-year.
- ARDELYX, INC. amortization of advance royalty for the quarter ending 2023-09-30 was $922.00K, a 10.95% increase year-over-year.
- ARDELYX, INC. amortization of advance royalty for the quarter ending 2023-06-30 was $968.00K, a 9580.00% increase year-over-year.
- ARDELYX, INC. amortization of advance royalty for the quarter ending 2023-03-31 was $969.00K.
- ARDELYX, INC. amortization of advance royalty for fiscal 2023 was $3.92M, a 134.55% increase from fiscal 2022.
- ARDELYX, INC. amortization of advance royalty for fiscal 2022 was $1.67M.
- ARDELYX, INC. amortization of advance royalty for fiscal 2021 was $0.00.
- ARDELYX, INC. amortization of advance royalty for fiscal 2020 was $0.00.
| Period end | Amortization of Advance Royalty 3 month | Amortization of Advance Royalty 6 month | Amortization of Advance Royalty 9 month | Amortization of Advance Royalty 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.99M derived: sum of 2 quarters · filed 2024-02-22 | $2.96M derived: sum of 3 quarters · filed 2024-02-22 | $3.92M 10-K · filed 2024-02-22 |
| 2023-09-30 | $922.00K 10-Q · filed 2023-10-31 | $1.89M derived: sum of 2 quarters · filed 2023-10-31 | $2.86M 10-Q · filed 2023-10-31 | $3.69M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-06-30 | $968.00K 10-Q · filed 2023-08-02 | $1.94M 10-Q · filed 2023-08-02 | $2.77M derived: sum of 3 quarters · filed 2024-02-22 | $3.60M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $969.00K 10-Q · filed 2023-05-03 | $1.80M derived: sum of 2 quarters · filed 2024-02-22 | $2.63M derived: sum of 3 quarters · filed 2024-02-22 | $2.64M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.66M derived: sum of 2 quarters · filed 2024-02-22 | $1.67M derived: sum of 3 quarters · filed 2024-02-22 | $1.67M 10-K · filed 2024-02-22 |
| 2022-09-30 | $831.00K 10-Q · filed 2023-10-31 | $841.00K derived: sum of 2 quarters · filed 2023-10-31 | $841.00K 10-Q · filed 2023-10-31 | $841.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $10.00K 10-Q · filed 2023-08-02 | $10.00K 10-Q · filed 2023-08-02 | $10.00K derived: sum of 3 quarters · filed 2024-02-22 | $10.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |